Antigen Spreading via Localized Administration Enhances Adoptive TCR-T Cell Therapy in Pancreatic Cancer

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Pancreatic cancer presents a significant challenge due to low mutational burden and limited tumor antigens for rejection.
• Existing cancer vaccines face hurdles in eliciting effective anti-tumor immunity in pancreatic cancer.

Purpose of the Study:

• To introduce ILvax, an ionic liquid formulation for localized tumor administration.
• To investigate ILvax's capacity to elicit a systemic, antigen-specific anti-tumor immune response.
• To evaluate ILvax's potential as a vaccine-like therapy for pancreatic cancer.

Main Methods:

• Localized tumor administration of ILvax.
• Analysis of Type 1 conventional dendritic cell (cDC1) migration and function.
• Assessment of antigen presentation cascade and T cell responses (endogenous CD8+ T cells and adoptive TCR-T cells).
• Evaluation of TCR-T cell metabolism shift towards oxidative phosphorylation (OXPHOS).

Main Results:

• ILvax elicits a systemic and antigen-specific anti-tumor immune response.
• ILvax facilitates cDC1 migration, enhancing antigen presentation and amplifying antigen-specific T cell responses.
• ILvax promotes antigen spreading, leading to expansion of adoptive TCR-T cells and a metabolic shift towards OXPHOS.
• Localized ILvax administration enhances both endogenous CD8+ T cells and adoptive TCR-T cells.

Conclusions:

• ILvax demonstrates a vaccine-like effect by generating a robust systemic anti-tumor immune response.
• ILvax represents a clinically translatable collaborative strategy for enhancing immunotherapy in pancreatic cancer.
• The study highlights the critical role of cDC1s in ILvax-mediated anti-tumor immunity.